Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Database grows for genetic tests

This article was originally published in The Gray Sheet

Executive Summary

Sixteen new genetic tests for diagnosis, prognosis and monitoring of non-cancer diseases and conditions are identified in a Dec. 9 draft technology assessment released by the Agency for Healthcare Research and Quality. According to the draft, the report aims to identify genetic tests for non-cancer conditions that are already in clinical practice and applicable to the Medicare population, as well as create one-page summaries on each test for a public electronic database that will separately include information on genetic tests for cancers. The tech assessment describes eight pharmacogenetic tests for non-cancer conditions - such as for warfarin dosing and sensitivity, and clopidogrel non-responsiveness - and eight tests for genetic disease association, including those that identify risk for psoriasis arthritis, heart disease and periodontal disease. AHRQ will take comments through Jan. 8, 2010

You may also be interested in...



Chloroquine ‘Approval’ For COVID-19 And The US FDA’s New Reality

Asking whether FDA’s decision to allow emergency use of two old anti-malarial drugs was ‘political’ misses the point. The issue already was political, and FDA’s action may well be the best way to keep some measure of federal control on supplies of a drug with important other uses.

Biopharma, Payers Seek National Guidelines For Prescribing Potential COVID-19 Drugs

Guidelines for health care providers could help prevent shortages as demand for possible treatments surge, groups say. Stakeholders also argue “Buy America” executive order would hamper drug access.

Becton Dickinson, BioMedomics Collaborate On Rapid Serology COVID-19 Test

BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.

Topics

UsernamePublicRestriction

Register

MT028297

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel